Tags

Type your tag names separated by a space and hit enter

[Thiomersal and immunisations].

Abstract

Thiomersal was used in the 1930s for the first time for the preservation of vaccines to prevent bacterial and fungal contamination. Thiomersal is an organic compound containing 49% mercury (Hg) by weight. It is generally well known that mercury and its compounds, including thiomersal, ethylmercury, and methylmercury, act as nephro- and neurotoxicants, however, at much higher doses than used in vaccines. In the 1990s the question of toxicity of thiomersal in vaccines was reassessed since the numbers of vaccines recommended for routine administration to infants and children, and therefore the cumulative thiomersal dose in children, increased in some countries. Various international committees (European Agency for the Evaluation of Medicinal Products, EMEA, US Public Health Service/American Academy of Pediatrics, Institute of Medicine, IOM) concluded after an extensive risk/benefit analysis that scientific evidence is inadequate to reject or explicitly recommend thiomerosal-containing vaccines for children. However (in line with the global goal of reducing exposure to mercury), they recommended promoting the elimination of thiomerosal from paediatric vaccines. This has largely been achieved in Germany. Today a child in Germany can be immunised in accordance with the official recommendations (STIKO) almost without the administration of thiomerosal (residual amounts). Results of new pharmacokinetic and epidemiological studies are discussed. The evidence available to date does not support the hypothesis of a potential relationship between neurodevelopmental disorders and thiomersal-containing vaccines.

Authors+Show Affiliations

Paul-Ehrlich-Institut, Langen. weika@pei.deNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

ger

PubMed ID

15583887

Citation

Weisser, K, et al. "[Thiomersal and Immunisations]." Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, vol. 47, no. 12, 2004, pp. 1165-74.
Weisser K, Bauer K, Volkers P, et al. [Thiomersal and immunisations]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004;47(12):1165-74.
Weisser, K., Bauer, K., Volkers, P., & Keller-Stanislawski, B. (2004). [Thiomersal and immunisations]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 47(12), pp. 1165-74.
Weisser K, et al. [Thiomersal and Immunisations]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004;47(12):1165-74. PubMed PMID: 15583887.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Thiomersal and immunisations]. AU - Weisser,K, AU - Bauer,K, AU - Volkers,P, AU - Keller-Stanislawski,B, PY - 2004/12/8/pubmed PY - 2005/4/23/medline PY - 2004/12/8/entrez SP - 1165 EP - 74 JF - Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz JO - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz VL - 47 IS - 12 N2 - Thiomersal was used in the 1930s for the first time for the preservation of vaccines to prevent bacterial and fungal contamination. Thiomersal is an organic compound containing 49% mercury (Hg) by weight. It is generally well known that mercury and its compounds, including thiomersal, ethylmercury, and methylmercury, act as nephro- and neurotoxicants, however, at much higher doses than used in vaccines. In the 1990s the question of toxicity of thiomersal in vaccines was reassessed since the numbers of vaccines recommended for routine administration to infants and children, and therefore the cumulative thiomersal dose in children, increased in some countries. Various international committees (European Agency for the Evaluation of Medicinal Products, EMEA, US Public Health Service/American Academy of Pediatrics, Institute of Medicine, IOM) concluded after an extensive risk/benefit analysis that scientific evidence is inadequate to reject or explicitly recommend thiomerosal-containing vaccines for children. However (in line with the global goal of reducing exposure to mercury), they recommended promoting the elimination of thiomerosal from paediatric vaccines. This has largely been achieved in Germany. Today a child in Germany can be immunised in accordance with the official recommendations (STIKO) almost without the administration of thiomerosal (residual amounts). Results of new pharmacokinetic and epidemiological studies are discussed. The evidence available to date does not support the hypothesis of a potential relationship between neurodevelopmental disorders and thiomersal-containing vaccines. SN - 1436-9990 UR - https://www.unboundmedicine.com/medline/citation/15583887/[Thiomersal_and_immunisations]_ L2 - https://dx.doi.org/10.1007/s00103-004-0943-z DB - PRIME DP - Unbound Medicine ER -